NCT00628303 is a Phase 3 clinical trial of Motavizumab in Wheezing, sponsored by MedImmune LLC.

Who is sponsoring NCT00628303?

NCT00628303 is sponsored by MedImmune LLC.

What drugs are being tested in NCT00628303?

Interventions in NCT00628303: Motavizumab, Placebo.

Is NCT00628303 still recruiting?

NCT00628303 is currently withdrawn. Last updated 30 July 2012.

Last reviewed 2012-07-30 · How we verify

NCT00628303

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of the Effect of Motavizumab Prophylaxis on Reduction of the Incidence of Serious Early Childhood Wheezing in Preterm Infants

Withdrawn Phase 3 Last updated 30 July 2012

What this trial tests

Phase 3 trial testing Motavizumab in Wheezing. Withdrawn.

Timeline

1 October 2010

Primary endpoint
1 February 2011

1 December 2011

Quick facts

Lead sponsor	MedImmune LLC
Phase	Phase 3
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	double
Primary purpose	treatment
Start date	1 October 2010
Primary completion	1 February 2011
Estimated completion	1 December 2011

Drugs / interventions tested

Motavizumab — full drug profile →
Placebo

Conditions studied

Wheezing — all drugs for Wheezing →

Sponsor

MedImmune LLC — full company profile →

Who can join

Under 6 Months, any sex, with Wheezing. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

The incidence of serious early childhood wheezing episodes
Time frame: Between 2nd and 3rd birthdays

Sponsor's own description

The primary objective of this study is to assess the efficacy of motavizumab compared to placebo when administered monthly to preterm infants during their first RSV season for the reduction of the incidence of serious early childhood wheezing from their 2nd through 3rd birthdays.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Overview of Current Therapeutics and Novel Candidates Against Influenza, Respiratory Syncytial Virus, and Middle East Respiratory Syndrome Coronavirus Infections.
Behzadi MA, Leyva-Grado VH. · · 2019 · cited 78× · PMID 31275265 · DOI 10.3389/fmicb.2019.01327
Motavizumab.
Cingoz O. · · 2009 · cited 25× · PMID 20065632 · DOI 10.4161/mabs.1.5.9496
Erratum to: Motavizumab
· 2010 · DOI 10.4161/mabs.2.5.12759

Verify or expand the search:

Other trials of Motavizumab

Trials testing the same drug.

NCT00435227 — A Study to Evaluate a Single Intramuscular Dose of Motavizumab to Treat Children With Respiratory Syncytial Virus (RSV) · Phase 2 · terminated
NCT00421304 — A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory · NA · completed
NCT00121108 — MEDI-524 (Motavizumab) for the Prevention of Respiratory Sycytial Virus (RSV) Disease Among Native American Indian Infan · Phase 3 · completed

Other recruiting trials for Wheezing

Currently open trials in the same condition.

NCT07044128 — Validate the Efficacy and the Safety of the Keikku Electronic Stethoscope for Its Indication and Intended Purpose, Under · recruiting
NCT06580600 — PREcision Medicine Directed Corticosteroids In Children With preSchool Wheeze · NA · recruiting
NCT05667701 — Soy Isoflavones For Inner City Infants At Risk For Asthma (SIRA) Study · Phase 2 · recruiting
NCT06603584 — Phenotypes of Preschool Wheezing Among Children Attending Sohag University Hospital · recruiting
NCT06311162 — Early Life Intervention in Pediatrics Supported by E-health - SMOKE · NA · recruiting

Other MedImmune LLC trials

Trials by the same sponsor.

NCT04145193 — Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC · Phase 2 · withdrawn
NCT04522323 — A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma · Phase 1 · active not recruiting
NCT03903718 — Evaluation of the Safety and Efficacy of a Monoclonal Antibody to Treat Influenza · Phase 2 · withdrawn
NCT04261075 — IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors. · Phase 1 · completed
NCT03889275 — A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00628303 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by MedImmune LLC
Last refreshed: 30 July 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00628303.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing